Date: 2014-01-10
Type of information: Preclinical data
phase: preclinical
Announcement:
Company: to-BBB (The Netherlands)
Product: 2B3-101
Action
mechanism: cytotoxic antibiotic. 2B3-101 is a glutathione pegylated liposomal doxorubicin. to-BBB has developed 2B3-101 by applying the G-Technology to the already marketed pegylated liposomal doxorubicin formulations (Caelyx®/Doxil®), by conjugating glutathione to the tips of the PEG.
Disease: glioma
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On January 10, 2014, to-BBB has announced the publication of non clinical data on its lead product 2B3-101 in Plos ONE. 2B3-101 glutathione pegylated liposomal doxorubicin, is being developed as a new treatment option for patients with brain cancer. In non clinical studies it was shown that 2B3-101 enhanced the delivery of the active compound doxorubicin to the brain. Furthermore, 2B3-101 significantly inhibited tumor growth in an experimental brain cancer model. Furthermore, this improved efficacy of 2B3-101 was supported by additional in vitro and in vivo experiments. Using an in vitro model, it was shown that 2B3-101 was actively and specifically taken up by blood-brain barrier endothelial cells, while Doxil/Caelyx mainly remained bound to the cells without substantial evidence of an active uptake process. These findings were confirmed in vivo, showing a higher brain retention with 2B3-101 compared to Doxil/Caelyx four days after the administration, while the plasma levels were comparable.
(Gaillard PJ, Appeldoorn CCM, Dorland R, van Kregten J, Manca F, et al. (2014) Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101). PLoS ONE 9(1): e82331. doi:10.1371/journal.pone)
